Mirati Therapeutics (MRTX) PT Raised to $51 at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
Tweet
Share
E-mailGet Alerts MRTX Hot Sheet
Price: $58.70 --0%
Rating Summary:
8 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Rating Summary:
8 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Join SI Premium – FREE
Morgan Stanley analyst Michael Ulz raised the price target on Mirati Therapeutics (NASDAQ: MRTX) to $51.00 (from $50.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- Datadog (DDOG) PT Lowered to $275 at TD Cowen
- Freshpet (FRPT) PT Lowered to $85 at DA Davidson
- Zimmer Biomet (ZBH) PT Raised to $102 at BMO Capital
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
